Navigation Links
BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Date:1/19/2011

NOVATO, Calif., Jan. 19, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease.

"We have a strong track record of quickly developing enzyme replacement therapies for unmet medical needs and expect to leverage our clinical and regulatory experience and manufacturing know-how in the development of BMN 701," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "There is a significant amount of interest in the medical community for a more effective treatment option for late-onset Pompe disease, and we believe, based on in vitro and in vivo nonclinical studies, that using our proprietary Glycosylation Independent Lysosomal Targeting, or GILT technology, BMN 701 has the potential to deliver more enzyme to lysosomes compared to traditional mannose-6-phosphate targeted approaches."  

The Phase 1/2 trial is an open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and clinical activity of BMN 701 administered as an intravenous infusion every two weeks at doses of 5 mg/kg, 10 mg/kg and 20 mg/kg.  The company expects to enroll approximately 30 patients between the ages of 13 and 65 years old with late-onset Pompe disease for a treatment period of 24 weeks.

About Pompe DiseasePompe disease, a lysosomal storage disorder, is a progressive degenerative disease of skeletal muscle including respiratory muscles such as diaphragm, and of heart muscle in infant-onset patients.  It is caused by a deficiency in the lysosomal enzyme acid alpha glucosidase which leads to the accumulation of glycogen in muscle cell lysosomes and results in cell death.  The incidence is one in 40,000 births. 
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015  CytRx Corporation (Nasdaq: ... specializing in oncology, today announced an interim analysis ... studies pairing aldoxorubicin with either gemcitabine or ifosfamide. ... ifosfamide with escalating doses of aldoxorubicin. The combinations ... the lowest dose level of aldoxorubicin (170 mg/m2), ...
(Date:5/4/2015)... YORK , May 4, 2015  FireflySci Inc., the newest member of the cuvette ... after launch, they have turned the cuvette industry on its head by offering scientists amazing support ... http://photos.prnewswire.com/prnh/20150501/213243LOGO Photo - http://photos.prnewswire.com/prnh/20150501/213244 ... ... ...
(Date:5/4/2015)... 4, 2015 The Pharmacy Workforce Center recently ... that pharmacy has shifted toward a female-dominated profession. With ... managers, there is an incredible opportunity for women to ... decade. In a new blog post ... Insights , Eden Sulzer, director of the Women ...
Breaking Medicine Technology:CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3Cardinal Health Expert Discusses Latest Research On Gender Gap In Pharmacy 2Cardinal Health Expert Discusses Latest Research On Gender Gap In Pharmacy 3
(Date:5/4/2015)... The University of California, Davis and ... initiative at UC Davis School of Medicine dedicated ... to advancing Latino health. , The program, called ... to Be Physicians, (“Prep Médico” for short) is ... and internship opportunities, a residential program, intensive language ...
(Date:5/4/2015)... Georgia (PRWEB) May 04, 2015 Each year, ... country to raise funds and awareness for breast cancer. This ... Surgery will be featured as the entertainment sponsor for the ... Cure” on May 9 at the Lenox Square Mall. , ... Atlanta race, and to raise $1.2 million. Perimeter Plastic Surgery ...
(Date:5/4/2015)... Johnson & Wales University (JWU) held a groundbreaking ceremony ... on Wednesday, April 22. , Johnson & Wales becomes the ... the re-alignment of Interstate-195. JWU’s new academic building, which will ... in Providence, is scheduled to be completed in July 2016. ... university purchased in 2012. , “It has long been our ...
(Date:5/4/2015)... May 04, 2015 The Lymphoma Research ... exclusively to funding innovative lymphoma research and serving the ... outreach initiatives and patient services – is set to ... Mayfair Farms in West Orange, NJ on June 1, ... for innovative research programs through LRF. , This year, ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Baptist ... Association/American Stroke Association’s Get With The Guidelines®-Stroke Gold ... Stroke Honor Roll. The award recognizes the hospital’s ... receive the most appropriate treatment according to nationally ... evidence. , To receive the Gold Plus Quality ...
Breaking Medicine News(10 mins):Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4
... loss to Argentina in a World Cup match in 1998 ... by 27 per cent. The fact that extreme stress and ... known to almost everyone.However, research carried out at the ... Argentina during the 1998 World Cup has provided further evidence ...
... The number of people suffering from spine problems is on ... disc and spinal canal stenosis. Herniated disc is more common ... spinal canal stenosis is common among// older people. Hitherto, both ... an incision of about 12cms to be made and the ...
... of the main concerns of teenagers heading back to school ... UT Southwestern Medical Center say that stress is one of ... stress produces increased secretion of the hormone androgen //which results ... likely to suffer from acne due to the hormonal changes ...
... new study involving twenty mothers and their full-term infants, ... regular sleep cycle. ,Dr. Sari Goldstein from Tel ... the perinatal // period helps infants coordinate their circadian ... clock that helps humans and other beings adjust to ...
... shown that smoking leads to damage of the protective reflexes ... from flowing back into the hroat and smoking causes damage ... chords if fluid enters the area, a condition known as ... by imaging the relex area before and after cigarettes. The ...
... study on both mice and humans are showing why some people ... that if you eat a fatty meal or snack - a ... cholesterol you absorb is strongly influenced by your genes. Experts know ... high fat diet is bad for you. But little has been ...
Cached Medicine News:
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... capability to quickly deliver up to 250 ... for powerful single-pulse ablation. This type of ... coldest and cleanest CO2 surgical laser available ... with the independent adjustment of pulse energy ...
... technology has allowed for perfecting mini-invasive endoscopic ... various pathologies with a considerable social impact. ... reducing the post-operatory times and represents a ... in all hospital structures.,DEKAs family of Nd:YAG ...
Medicine Products: